Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …

Over the past decade, non-coding RNA-based therapeutics have proven as a great potential
for the development of targeted therapies for cancer and other diseases. The discovery of …

Gastric cancer (GC) is the fifth most common type of cancer and the third leading cause of
death due to cancer worldwide. The gastric mucosa often undergoes many years of …

Since the discovery of the first microRNA (miRNA), the exploration of miRNA biology has
come to a new era in recent decades. Monumental studies have proven that miRNAs can be …

Precision medicine has greatly aided in improving health outcomes using earlier diagnosis
and better prognosis for chronic diseases. It makes use of clinical data associated with the …

According to recent studies, long non‐coding RNA X‐inactive specific transcript (XIST) is
involved in the development and progression of many malignant tumors including …

With the first RNA interference (RNAi) drug (ONPATTRO (patisiran)) on the market, we
witness the RNAi therapy field reaching a critical turning point, when further improvements in …

Abstract Background P73 antisense RNA 1 T (non-protein coding), also known as TP73-
AS1, is a long non-coding RNA (lncRNA) which is involved in cell proliferation and the …

Uveal melanoma is the most common type of intraocular cancer with a low mean annual
incidence of 5-10 cases per million. Tumours are located in the choroid (90%), ciliary body …

Cancer 'stemness' is fundamental to cancer existence. It defines the ability of cancer cells to
indefinitely perpetuate as well as differentiate. Cancer stem cell populations within a …